Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance

J. J. Tosoian, H. D. Patel*, M. Mamawala, P. Landis, S. Wolf, D. J. Elliott, J. I. Epstein, H. B. Carter, A. E. Ross, L. J. Sokoll, C. P. Pavlovich

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background:: To assess the utility of urinary prostate cancer antigen 3 (PCA3) as both a one-time and longitudinal measure in men on active surveillance (AS). Methods:: The Johns Hopkins AS program monitors men with favorable-risk prostate cancer with serial PSA, digital rectal examination (DRE), prostate magnetic resonance imaging and prostate biopsy. Since 2007, post-DRE urinary specimens have also been routinely obtained. Men with multiple PCA3 measures obtained over ⩾3 years of monitoring were included. Utility of first PCA3 score (fPCA3), subsequent PCA3 (sPCA3) and change in PCA3 were assessed for prediction of Gleason grade reclassification (GR, Gleason score >6) during follow-up. Results:: In total, 260 men met study criteria. Median time from enrollment to fPCA3 was 2 years (interquartile range (IQR) 1–3) and from fPCA3 to sPCA3 was 5 years (IQR 4–6). During median follow-up of 6 years (IQR 5–8), 28 men (11%) underwent GR. Men with GR had higher median fPCA3 (48.0 vs 24.5, P=0.007) and sPCA3 (63.5 vs 36.0, P=0.002) than those without GR, while longitudinal change in PCA3 did not differ by GR status (log-normalized rate 0.07 vs 0.06, P=0.53). In a multivariable model including age, risk classification and PSA density, fPCA3 remained significantly associated with GR (log(fPCA3) odds ratio=1.77, P=0.04). Conclusions:: PCA3 scores obtained during AS were higher in men who underwent GR, but the rate of change in PCA3 over time did not differ by GR status. PCA3 was a significant predictor of GR in a multivariable model including conventional risk factors, suggesting that PCA3 provides incremental prognostic information in the AS setting.

Original languageEnglish (US)
Pages (from-to)339-342
Number of pages4
JournalProstate Cancer and Prostatic Diseases
Volume20
Issue number3
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance'. Together they form a unique fingerprint.

  • Cite this

    Tosoian, J. J., Patel, H. D., Mamawala, M., Landis, P., Wolf, S., Elliott, D. J., Epstein, J. I., Carter, H. B., Ross, A. E., Sokoll, L. J., & Pavlovich, C. P. (2017). Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate Cancer and Prostatic Diseases, 20(3), 339-342. https://doi.org/10.1038/pcan.2017.16